share
hit
by
m
drug
suspens
share
in
elan
and
biogen
idec
plung
on
monday
a
the
firm
suspend
sale
of
new
multipl
sclerosi
drug
tysabri
after
a
patient
death
in
the
u
on
the
new
york
stock
exchang
share
in
irelandbas
elan
lost
while
u
partner
biogen
idec
shed
the
firm
took
action
after
the
death
from
a
central
nervou
system
diseas
and
a
suspect
case
of
the
condit
the
case
cite
involv
the
use
of
both
tysabri
and
avonex
biogen
idec
exist
multipl
sclerosi
drug
the
compani
said
they
have
no
report
of
the
rare
condit
progress
multifoc
leukoencephalopathi
pml
in
patient
take
either
tysabri
or
avonex
alon
tysabri
wa
approv
for
use
in
the
u
last
novemb
and
wa
wide
tip
to
becom
the
world
lead
multipl
sclerosi
treatment
the
compani
will
work
with
clinic
investig
to
evalu
tysabritr
patient
and
will
consult
with
lead
expert
to
better
understand
the
possibl
risk
of
pml
the
two
firm
said
in
a
statement
the
outcom
of
these
evalu
will
be
use
to
determin
possibl
reiniti
of
dose
in
clinic
trial
and
futur
commerci
avail
analyst
had
believ
the
product
would
provid
a
new
growth
opportun
for
biogen
idec
which
had
face
increas
competit
from
rival
to
avonex
elan
onc
the
biggest
firm
on
the
irish
stock
exchang
wa
also
expect
to
receiv
a
boost
from
the
new
product
an
inquiri
into
elan
account
in
brought
the
group
close
to
bankruptci
but
the
firm
ha
been
rebuild
itself
sinc
with
it
share
price
increas
by
almost
fourfold
last
year
most
of
the
valu
in
the
compani
wa
in
tysabri
said
ian
hunter
at
goodbodi
stockbrok
in
dublin
now
there
a
question
mark
over
it
elan
finish
down
at
while
biogen
fell
to
share
in
uk
pharmaceut
firm
phytopharm
close
down
at
penc
on
the
london
stock
exchang
on
monday
after
it
said
a
partner
wa
set
to
pull
out
of
a
deal
on
an
experiment
alzheim
diseas
treatment
phytopharm
said
japan
yamanouchi
pharmaceut
wa
like
to
end
a
licens
agreement
prompt
analyst
to
rais
question
over
the
level
of
it
futur
cash
reserv
